Form 4: Opus Genetics President Executes Tax-Related Stock Sale

Benjamin R. Yerxa, President of Opus Genetics, sold 7,470 shares to satisfy tax withholding obligations related to RSU vesting.

Summary

• Benjamin R. Yerxa, President of Opus Genetics, Inc., sold 7,470 shares of common stock on April 23, 2026.
• The shares were sold at a weighted average price of $5.2371 per share.
• The transaction was non-discretionary, executed automatically to cover tax withholding obligations arising from the vesting of restricted stock units.
• Following the transaction, the reporting person retains beneficial ownership of 711,535 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was a mandatory administrative action rather than a strategic divestment.

Positives

• The sale was mandatory and non-discretionary, indicating it was not a signal of lack of confidence in the company's future performance.

Negatives

• Reduction in the direct equity stake held by the company President.

Risks

• Market volatility affecting the value of remaining equity holdings.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this filing.

Management Comments

• The transaction does not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that automatic sell-to-cover transactions are standard corporate governance practices for executives receiving equity-based compensation, and they generally do not reflect management sentiment regarding company health.

Comparison to Industry Standards

• The transaction aligns with standard industry practices for executive tax compliance regarding RSU vesting.

Stakeholder Impact

• Minimal impact on shareholders as the sale was non-discretionary and limited in volume.

Next Steps

• None mentioned.

Key Dates

Keywords

Opus Genetics, IRD, Insider Trading, Form 4, Equity Compensation, Tax Withholding